Ukoniq
Ukoniq (umbralisib) is a medication taken by mouth to treat the blood cancers called marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was approved by the FDA in 2021, but taken off the market shortly after due to safety concerns. It has been discontinued and is no longer available in the United States.
What is Ukoniq (umbralisib)?
What is Ukoniq (umbralisib) used for?
- Marginal zone lymphoma (MZL)
- Follicular lymphoma (FL)
Drug facts
Common questions about Ukoniq (umbralisib)
Ukoniq (umbralisib) is an antineoplastic (anticancer) medication used to treat MZL and FL, two types of B-cell lymphomas (cancers that affect white blood cells). In MZL, it's only used in people who've previously received at least one different kind of treatment. In FL, this medication is used for people who've received at least three different kinds of treatments before. In both cases, the previous treatments either didn't work (refractory) or the cancer still came back (relapsed). Ukoniq (umbralisib) is a kinase inhibitor that blocks certain proteins important for cancer cell growth and survival.
No, Ukoniq (umbralisib) has been discontinued and is no longer available in the United States.
In 2022, the FDA took away its approval for Ukoniq (umbralisib) due to safety concerns. An ongoing study showed a possible higher risk of death in people receiving this medication.
If you've been prescribed Ukoniq (umbralisib), work with your provider to find an alternative treatment. You can dispose of Ukoniq (umbralisib) at a drug take-back location, or in your household trash by mixing it with dirt or coffee grounds and sealing the mixture in a plastic bag. Make sure to remove all of your personal information first to protect your privacy.
How to save using GoodRx
Ukoniq (umbralisib) dosage
Typical dosage for Ukoniq (umbralisib)
